Cigna (CI) ended the recent trading session at $298.88, demonstrating a +0.36% swing from the preceding day's closing price. This change lagged the S&P 500's 0.76% gain on the day. On the other hand, the Dow registered a gain of 0.59%, and the technology-centric Nasdaq increased by 1.12%.Heading into today, shares of the health insurer had lost 0.54% over the past month, lagging the Medical sector's gain of 1.57% and the S&P 500's gain of 2.5% in that time.Market participants will be closely following the f ...

Monty Rakusen Investment Thesis In this article, I explore The Cigna Group's (NYSE:CI) potential, spotlighted by its innovative subsidiary Evernorth. The surge in Obamacare enrollments is a supporting factor to this thesis. I read into the company's leadership changes and strategic decisions, such as offloading its Medicare Advantage business. Many of these sections you’ll read point me to the company’s growth trajectory focus. Additionally, insights from the JPMorgan Healthcare Conference help us recog ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Cigna (CI) reports results for the quarter ended December 2023. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on February 2. On the ...

Brian Evanko to continue as Chief Financial Officer, will serve as new President and CEO of Cigna Healthcare Ann Dennison to join The Cigna Group as Deputy Chief Financial Officer Mike Triplett to retire by end of 2024 and Bryan Holgerson promoted to President of U.S. Commercial for Cigna Healthcare Eric Palmer to assume expanded role leading enterprise strategy and corporate development, will continue as President and CEO of Evernorth Health Services BLOOMFIELD, Conn., Jan. 17, 2024 /PRNewswire/ -- The C ...

BLOOMFIELD, Conn., Jan. 11, 2024 /PRNewswire/ -- Global health company The Cigna Group (NYSE:CI) will release its fourth quarter 2023 financial results on Friday, February 2, 2024, and will host a conference call the same day. Fourth quarter 2023 financial results will be released no later than 6:30 a.m. Eastern Time (ET). Management will review these results on a conference call beginning at 8:30 a.m. ET. The call-in numbers are as follows: Live Call(888) 566-1889 (Domestic)(773) 799-3989 (International)Pa ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Cigna (CI) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Cigna is a member of the Medical sector. This group includes 1077 individual stocks and currently holds a Zacks Sector Rank of #3. The Zacks Sector Rank considers 16 different groups, m ...

Summary of Cigna Group's J.P. Morgan 42nd Annual Healthcare Conference Company Overview - **Company**: Cigna Group (NYSE: CI) - **Participants**: - David Cordani - President, Chief Executive Officer & Chair - Eric Palmer - Chief Executive Officer & President, Evernorth - **Date**: January 9, 2024 Key Points 1. Strong Performance in 2023 - Cigna reported a strong performance in 2023, continuing a track record of organic growth across various operating platforms, including PBM, commercial business, international benefits, and government benefits [3][4][8] 2. EPS Guidance for 2024 - The company reiterated its EPS outlook for 2024 at least $28, which is above the high end of its growth algorithm of 10% to 13% EPS growth over time [5][8] 3. Capital-Light Business Model - Cigna operates a capital-light, service-oriented portfolio, allowing for quick conversion of operating cash flow to deployable cash flow, providing strategic advantages in a fluid business environment [6][8] 4. Innovations in Pharmacy and Healthcare - Cigna is focusing on pharmacy innovations, particularly in pharmacological advancements like GLP-1s, and aims to optimize clinical protocols for better value for patients and financiers [7][8] 5. Government Benefits Business - Cigna is committed to expanding its capabilities in the government services portfolio, including Medicare and Medicaid, and sees growth potential in this area [14][15] 6. Evernorth's Growth and Strategy - Evernorth is positioned to reduce fragmentation in healthcare delivery and improve health outcomes through partnerships, such as with VillageMD, focusing on risk-bearing and performance-based models [18][19][21] 7. Market Trends and Client Needs - There is a trend of point solution fatigue among employers, leading to a demand for more integrated healthcare solutions and precision in care delivery [40][70] 8. Retention and Growth in PBM - Cigna's PBM business is experiencing strong retention and growth, with innovations in product offerings and a focus on client satisfaction [25][26][27] 9. Legislative Environment for PBMs - The PBM industry is under scrutiny, with potential legislative changes expected. Cigna is proactively engaging with officials to ensure transparency and value delivery [62][64][66] 10. Biosimilars and Market Adoption - Cigna anticipates increased adoption of biosimilars, particularly for high-cost medications like HUMIRA, which is expected to improve affordability for clients [58][60][61] 11. Commercial Business Outlook - Cigna's commercial business is expected to grow, particularly in the Select segment, despite anticipated softening in the employment landscape [67][70][71] Additional Insights - Cigna emphasizes the importance of aligning incentives in value-based care arrangements, which can involve shared risk with manufacturers or providers [46][48] - The company is adapting to market changes, including the potential resurgence of mail-order pharmacy services due to evolving consumer preferences [54][57] This summary encapsulates the key insights and strategic directions discussed during the conference, highlighting Cigna's robust performance, innovative approaches, and proactive engagement in the healthcare landscape.

The Cigna Group (NYSE:CI) J.P. Morgan 42nd Annual Healthcare Conference January 9, 2024 10:30 AM ET Company Participants David Cordani - President, Chief Executive Officer & Chair Eric Palmer - Chief Executive Officer & President, Evernorth Conference Call Participants Lisa Gill - JPMorgan Lisa Gill Good Morning. My name is Lisa Gill, and I'm Head of Healthcare Services for JPMorgan. It is with great pleasure this morning that we have with us Cigna Health. With us this morning, we have CEO, David Cordani; a ...

Each earnings reporting season, you can count on a flurry of articles with headlines saying companies “beat” consensus estimates for quarterly profits. But that “success” alone means nothing. A 70% “beat rate” among the S&P 500 is typical. And an earnings beat may be a net loss that was lower than expected. It is as if companies in their guidance and analysts working for brokerage firms underestimate to set up the beats.The U.S. earnings season will begin on Friday when the largest U.S. banks report their f ...

The Cigna Group (CI) is reportedly in advanced talks to divest its Medicare Advantage business. Per a Wall Street Journal report, Health Care Service Corporation is expected to acquire the business from Cigna in a deal that can be valued at $3-$4 billion. Shares of CI fell 2.1% yesterday.The potential acquirer, Health Care Service Corporation, is a Blue Cross Blue Shield licensee in five states, including Illinois and Texas. An announcement regarding the deal is expected to be made within the coming days. L ...